Literature DB >> 25138757

A comparison of methods used to evaluate mobility performance in the visually impaired.

Kevin J Warrian1, L Jay Katz1, Jonathan S Myers1, Marlene R Moster1, Michael J Pro1, Sheryl S Wizov1, George L Spaeth1.   

Abstract

PURPOSE: To compare three different approaches to measuring mobility performance when evaluating the visually impaired.
METHODS: 488 participants, including 192 glaucoma, 112 age-related macular degeneration, 91 diabetic retinopathy and 93 healthy volunteers, completed the Assessment of Disability Related to Vision (ADREV) mobility course. The performance of participants on the mobility course was evaluated by noting errors made and time required for completion. Errors noted and time taken were compared using multivariate logistic regression to determine which measurement better differentiated patients with visual disease from healthy volunteers. Multivariate logistic regression was also used to evaluate the combined metric of ADREV errors divided by time to determine its ability to discriminate participants with visual disease from healthy volunteers.
RESULTS: Errors noted and time taken while ambulating through the standardised mobility course shared a weak but statistically significant association (Pearson's r=0.36, p<0.05). After controlling for demographic and medical comorbidities, logistic regression analysis revealed that errors noted were better at discriminating individuals with visual disease from healthy volunteers (OR 2.8-4.9, 95% CI 1.5 to 10.3) compared with the time taken for mobility course completion (OR 1.1, 95% CI 1.0 to 1.2). These findings were consistent across all comparisons between healthy volunteers and participants with each type of visual impairment. Finally, the combined metric of ADREV errors divided by time was far more predictive of visual disease compared with either time taken or errors noted during mobility testing (OR 11.0-17.7, 95% CI 3.6 to 77.1).
CONCLUSIONS: A validated scoring system based on errors is more effective when assessing visual disability during mobility testing than recording the time taken for course completion. The combined metric of ADREV errors noted divided by time taken was most predictive of all the methods used to evaluate visual disability during mobility testing. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Degeneration; Glaucoma; Macula; Retina; Vision

Mesh:

Year:  2014        PMID: 25138757     DOI: 10.1136/bjophthalmol-2014-305324

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  Harmonization of Outcomes and Vision Endpoints in Vision Restoration Trials: Recommendations from the International HOVER Taskforce.

Authors:  Lauren N Ayton; Joseph F Rizzo; Ian L Bailey; August Colenbrander; Gislin Dagnelie; Duane R Geruschat; Philip C Hessburg; Chris D McCarthy; Matthew A Petoe; Gary S Rubin; Philip R Troyk
Journal:  Transl Vis Sci Technol       Date:  2020-07-16       Impact factor: 3.283

2.  A novel, wearable, electronic visual aid to assist those with reduced peripheral vision.

Authors:  Ffion E Brown; Janice Sutton; Ho M Yuen; Dylan Green; Spencer Van Dorn; Terry Braun; Angela J Cree; Stephen R Russell; Andrew J Lotery
Journal:  PLoS One       Date:  2019-10-15       Impact factor: 3.240

3.  Objective Assessment of Activity Limitation in Glaucoma with Smartphone Virtual Reality Goggles: A Pilot Study.

Authors:  Rachel L Z Goh; Yu Xiang George Kong; Colm McAlinden; John Liu; Jonathan G Crowston; Simon E Skalicky
Journal:  Transl Vis Sci Technol       Date:  2018-01-23       Impact factor: 3.283

4.  Assessing Photoreceptor Status in Retinal Dystrophies: From High-Resolution Imaging to Functional Vision.

Authors:  José-Alain Sahel; Kate Grieve; Chloé Pagot; Colas Authié; Saddek Mohand-Said; Michel Paques; Isabelle Audo; Karine Becker; Anne-Elisabeth Chaumet-Riffaud; Line Azoulay; Emmanuel Gutman; Thierry Léveillard; Christina Zeitz; Serge Picaud; Deniz Dalkara; Katia Marazova
Journal:  Am J Ophthalmol       Date:  2021-05-14       Impact factor: 5.258

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.